..
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City
California
94404
U.S.A.
Phone:
800-GILEAD-5 or 650-574-3000
Fax:
650-522-5800
|
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
Key Contacts:
John C. Martin, PhD, Chairman and Chief Executive Officer
John F. Milligan, PhD, President and Chief Operating Officer
Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer
Kevin Young, Executive Vice President, Commercial Operations
Gregg Alton, Executive Vice President, Corporate and Medical Affairs
Kristen Metza, Senior Vice President, Human Resources
Robin Washington, Senior Vice President and Chief Financial Officer
Susan Hubbard, Vice President, Investor Relations
Amy Flood, Vice President, Public Affairs
Email:
Ownership:
Public
Web Site:
Gilead Sciences, Inc.
Employees:
4,000
Symbol: GILD
|
|
|
Company News |
Gilead Sciences, Inc. (GILD) To Present At The NASDAQ OMX 30th Investor Program On Tuesday, December 3
12/3/2013 7:18:38 AM
More...
|
Idenix Pharmaceuticals, Inc. (IDIX) Files Patent Infringement And Interference Lawsuits Against Gilead Sciences, Inc. (GILD)
12/2/2013 9:34:08 AM
More...
|
European CHMP Adopts Positive Opinion for Gilead Sciences, Inc. (GILD)’ Sovaldi® For The Treatment Of Chronic Hepatitis C Infection
11/22/2013 10:10:36 AM
More...
|
Gilead Sciences, Inc. (GILD)'s Idelalisib Reduced Rate Of Disease Progression Or Death In Phase 3 Study
11/18/2013 8:24:40 AM
More...
|
European Commission (EC) Approves Gilead Sciences, Inc. (GILD)'s Vitekta™, To Treat HIV-1 Infection
11/18/2013 7:41:22 AM
More...
|
Gilead Sciences, Inc. (GILD) To Present At The Credit Suisse 2013 Healthcare Conference On Wednesday, November 13
11/13/2013 10:49:06 AM
More...
|
Gilead Sciences, Inc. (GILD) to Present Data on Oncology Pipeline at American Society of Hematology Annual Meeting
11/7/2013 8:47:39 AM
More...
|
Gilead Sciences, Inc. (GILD) Release: New Web Portal Explains the Affordable Care Act - "Obamacare"- for People With HIV
11/5/2013 7:45:30 AM
More...
|
Gilead Sciences, Inc. (GILD) Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation
11/4/2013 10:48:27 AM
More...
|
Gilead Sciences, Inc. (GILD) Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV
11/4/2013 10:47:21 AM
More...
|
|
|
|